Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: A randomized double-blind clinical trial

Hypertension Research

Volumn 34, Issue 9, 2011, Pages 1035-1040

  Cicero, Arrigo F G ^a   Rosticci, Martina ^a   Gerocarni, Beatrice ^a   Bacchelli, Stefano ^a   Veronesi, Maddalena ^a   Strocchi, Enrico ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Blood pressure; cardiac output; lactotripeptides; pulse wave velocity

Indexed keywords

ISOLEUCYLPROLYLPROLINE; LACTOTRIPEPTIDE DERIVATIVE; PLACEBO; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FRUIT JUICE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; STRESS; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

ADULT; AGED; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIAC OUTPUT; CASEINS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PULSATILE FLOW; STRESS, PHYSIOLOGICAL;

EID: 80052507804     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.92     Document Type: Article

References (26)

1. Miller III ER, Erlinger TP, Appel LJ. The effects of macronutrients on blood pressure and lipids: an overview of the DASH and OmniHeart trials. Curr Atheroscler Rep 2006; 8: 460-465. (Pubitemid 44697798)
2. Pérez-López FR, Chedraui P, Haya J, Cuadros JL. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas 2009; 64: 67-79.
3. Pripp AH. Effect of peptides derived from food proteins on blood pressure: a metaanalysis of randomized controlled trials. Food Nutr Res 2008; 52: 1-9.
4. Murray BA, FitzGerald RJ. Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 2007; 13: 773-791. (Pubitemid 46591099)
5. FitzGerald RJ, Meisel H. Milk protein-derived peptide inhibitors of angiotensin-Iconverting enzyme. Br J Nutr 2000; 84 (Suppl 1): S33-S37. (Pubitemid 32106827)
6. Cicero AFG, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens 2010; 25: 425-436.
7. Germino FW, Neutel J, Nonaka M, Hendler SS. The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J Clin Hypertens 2010; 12: 153-159.
8. Yamasue K, Morikawa N, Mizushima S, Tochikubo O. The blood pressure lowering effect of lactotoripeptides and salt intake in 24-h ambulatory blood pressure measurements. Clin Exp Hypertens 2010; 32: 214-220.
9. Cicero AFG, Rosticci M, Veronesi M, Bacchelli S, Strocchi E, Melegari C, Grandi E, Borghi C. Haemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, cross-over clinical trial. J Med Food 2010; 13: 1363-1368.
10. van Mierlo LA, Koning MM, van der Zander K, Draijer R. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies. Am J Clin Nutr 2009; 89: 617-623.
11. Yoshizawa M, Maeda S, Miyaki A, Misono M, Choi Y, Shimojo N, Ajisaka R, Tanaka H. Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. Am J Hypertens 2010; 23: 368-372.
12. Yoshizawa M, Maeda S, Miyaki A, Misono M, Choi Y, Shimojo N, Ajisaka R, Tanaka H. Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. Am J Physiol Heart Circ Physiol 2009; 297: H1899-H1903.
13. Nakamura T, Mizutani J, Sasaki K, Yamamoto N, Takazawa K. Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: a preliminary study. J Med Food 2009; 12: 1221-1226.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the Management of Arterial Hypertension. ESH-ESC Practice Guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 2007; 25: 1751-1762. (Pubitemid 47356612)
15. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716. (Pubitemid 40216499)
16. Madin K, Iqbal P. Twenty four hour ambulatory blood pressure monitoring: a new tool for determining cardiovascular prognosis. Postgrad Med J 2006; 82: 548-551. (Pubitemid 44476208)
17. Monahan KD, Dyckman DJ, Ray CA. Effect of acute hyperlipidemia on autonomic and cardiovascular control in humans. J Appl Physiol 2007; 103: 162-169. (Pubitemid 47092288)
18. Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 2010; 74: 24-33.
19. Sodolski T, Kutarski A. Impedance cardiography: a valuable method of evaluating haemodynamic parameters. Cardiol J 2007; 14: 115-126. (Pubitemid 46656819)
20. Borghi C, Veronesi M, Cosentino E, Cicero AF, Kuria F, Dormi A, Ambrosioni E. Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. J Hypertens 2007; 25: 2051-2057. (Pubitemid 47476301)
21. Wuerzner G, Peyrard S, Blanchard A, Lalanne F, Azizi M. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens 2009; 27: 1404-1409.
22. van der Zander K, Bots ML, Bak AA, Koning MM, de Leeuw PW. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Am J Clin Nutr 2008; 88: 1697-1702.
23. Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure: results from a doubleblind randomized controlled trial. Hypertension 2008; 51: 399-405. (Pubitemid 351159956)
24. Germino FW, Neutel J, Nonaka M, Hendler SS. The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J Clin Hypertens 2010; 12: 153-159.
25. Boutouyrie P, Laurent S, Briet M. Importance of arterial stiffness as cardiovascular risk factor for future development of new type of drugs. Fundam Clin Pharmacol 2008; 22: 241-246. (Pubitemid 351712895)
26. Hirota T, Ohki K, Kawagishi R, Kajimoto Y, Mizuno S, Nakamura Y, Kitakaze M. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 2007; 30: 489-496. (Pubitemid 47083118)